385 related articles for article (PubMed ID: 23574784)
1. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
2. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
3. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
4. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Hjortkjær M; Waldstrøm M; Jakobsen A; Kanstrup H; Søgaard-Andersen E; Dahl Steffensen K
Int J Gynecol Pathol; 2017 Mar; 36(2):180-189. PubMed ID: 27362900
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
von Minckwitz G; Müller BM; Loibl S; Budczies J; Hanusch C; Darb-Esfahani S; Hilfrich J; Weiss E; Huober J; Blohmer JU; du Bois A; Zahm DM; Khandan F; Hoffmann G; Gerber B; Eidtmann H; Fend F; Dietel M; Mehta K; Denkert C
J Clin Oncol; 2011 Jun; 29(16):2150-7. PubMed ID: 21519019
[TBL] [Abstract][Full Text] [Related]
7. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
8. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer.
Klauschen F; von Winterfeld M; Stenzinger A; Sinn BV; Budczies J; Kamphues C; Bahra M; Wittschieber D; Weichert W; Striefler J; Riess H; Dietel M; Denkert C
Histopathology; 2012 Sep; 61(3):409-16. PubMed ID: 22384823
[TBL] [Abstract][Full Text] [Related]
9. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
10. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
11. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
12. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
13. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA
Cancer; 2016 Jun; 122(12):1844-52. PubMed ID: 27062051
[TBL] [Abstract][Full Text] [Related]
14. Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-κB pathway.
Darb-Esfahani S; Sinn BV; Rudl M; Sehouli J; Braicu I; Dietel M; Denkert C
Int J Gynecol Pathol; 2014 Jan; 33(1):16-22. PubMed ID: 24300530
[TBL] [Abstract][Full Text] [Related]
15. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
Godoy H; Mhawech-Fauceglia P; Beck A; Miller A; Lele S; Odunsi K
Int J Gynecol Pathol; 2011 Mar; 30(2):139-44. PubMed ID: 21293287
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I; Frankum JR; Konde A; Miller RE; Rehman FL; Brough R; Campbell J; Sims D; Rafiq R; Hooper S; Chen L; Kozarewa I; Assiotis I; Fenwick K; Natrajan R; Lord CJ; Ashworth A
Cancer Res; 2014 Jan; 74(1):287-97. PubMed ID: 24240700
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
18. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
Davidson B; Reich R; Lazarovici P; Nesland JM; Skrede M; Risberg B; Tropé CG; Flørenes VA
Clin Cancer Res; 2003 Jun; 9(6):2248-59. PubMed ID: 12796393
[TBL] [Abstract][Full Text] [Related]
19. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB
J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]